This phase I/II trial is evaluating an immunotherapy combination (MK-4280 and Pembrolizumab) in patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell Lymphoma.
This trial is treating patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell Lymphoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies
This is a non-randomised trial, including Part A (dose escalation) and Part B (dose expansion) treatment phases. In Part A, patients will be assigned to receive a standard (200mg) dose of Pembrolizumab followed by varying doses (A, B or C) of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. In Part B, patients will be assigned to groups based on their diagnosis. All patients will receive the standard dose (200mg) of Pembrolizumab followed by the recommended phase II dose of MK-4280 by infusion on Day 1 of each 3-week cycle for up to 35 cycles.
Recruiting Hospitals Read More